Hoya invests in shape-changing, accommodating IOL

Article

Hoya has formed a strategic partnership with Adoptics of Switzerland by funding the development of a shape-changing accommodating intraocular lens (AIOL).

Hoya has formed a strategic partnership with Adoptics of Switzerland by funding the development of a shape-changing accommodating intraocular lens (AIOL).

Dr David Chang, a clinical professor of ophthalmology at the University of California, San Francisco, said: “This AIOL technology is based on a novel and clever concept that has the potential to produce a very powerful accommodative effect - something which remains the 'Holy Grail' of cataract and refractive surgery. ” Commenting on the investment, Tom Dunlap, President and CEO of Hoya Surgical Optics, stated: “Hoya recognizes the significant impact that the proprietary AIOL technology will have in addressing both the presbyopic and myopic challenges of patients with cataracts. We believe the shape-changing AIOL is the most efficient and consistent way to provide the power range necessary for true accommodation and to achieve spectacle-free vision for many patients. ”



Adoptics' founder and CEO, Dr Khalid Mentak, said: “This strategic partnership with HOYA will help us bring to market the first shape-changing accommodating IOL that closely mimics the mode of action of young crystalline lens.” Adoptics’ technology uses a proprietary fluid-based refraction system within an IOL to create significant changes in the refractive power of the human visual system. Unlike other presbyopia-correcting IOLs, the Adoptics lens does not require movement of the optic within the eye to change refractive power. The refractive surface of the IOL itself changes shape in response to movement of the ciliary muscles, the natural process of accommodation in the human eye.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.